Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors
Featuring
Associate Professor Lee-Ling Lim | Malaysia
Related content
Document ID: PC-MY-103248
Lee-Ling Lim (Malaysia)
Why is organ protection crucial in patients with cardiorenal metabolic conditions?
PDF
How can you get the most out of SGLT2 inhibitors?
PDF
How do SGLT2 inhibitors protect the heart and kidneys in addition to providing glucose control?
PDF
Medication guideline for type 2 diabetes
PDF